Results 31 to 40 of about 21,874 (160)

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

BMC Cancer, 2021
Background Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 13–23% of all GC cases and patients with HER2 overexpression exhibit a ...
Gang Ning, Qihui Zhu, Wonyoung Kang, Hamin Lee, Leigh Maher, Yun-Suhk Suh, Michael Michaud, Mayerlin Silva, Jee Young Kwon, Chengsheng Zhang, Charles Lee   +10 more
doaj   +1 more source

REGγ Suppresses Ferroptosis and Induces Drug Resistance by Degrading WDR6 in Chondrosarcoma

Advanced Science, EarlyView.
Here, we identified REGγ as a susceptibility factor in chondrosarcoma. Our study demonstrates that abnormally activated REGγ‐20S proteasome promotes chondrosarcoma development and progression. Further validation in animal models revealed that blocking REGγ function induced ferroptosis, suppressed malignant progression of chondrosarcoma, and uncovered a
Fanrong Liu, Shihui Shen, Dongxia Li, Peilin Shi, Jiaming Xu, Tongxin Lv, Yingying Du, Jingwei Zhang, Bo Yang, Hansen Chen, Zhuoya Peng, Wenjie Ren, Lu Zhang, Sheng Cheng, Tongjin Yin, Wencai Sheng, Lei Li, Juan Wu, Qingcheng Yang, Shuogui Xu, Wei Zheng   +20 more
wiley   +1 more source

RHINO: An Integrative Multi‐Omics Framework Linking Circadian Physiology to Precision Medicine

Advanced Science, EarlyView.
RHINO (RHythmic Interacting Network for multi‐Omics) is an integrative framework that maps circadian regulation across diverse genetic and disease contexts and prioritizes druggable circadian targets. Released as an AI‐powered interactive web portal, RHINO unifies genetic, regulatory, disease, and drug–target information, enabling context‐specific ...
Ying Chen, Chengxuan Chen, Dishu Zhou, Panpan Liu, Roberto E. López‐Valiente, Yuan Liu, Cam Mong La, Isabella Beraldo Xavier, Sean M. Hartig, Pradip Saha, Zheng Sun, Leng Han, Dongyin Guan   +12 more
wiley   +1 more source

Clinical data mining reveals analgesic effects of lapatinib in cancer patients

Scientific Reports, 2021
Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a promising target for a next generation of anti-inflammatory drugs that are not expected to have the side effects of currently available anti-inflammatory drugs.
Shuo Zhou, Fang Zheng, Chang-Guo Zhan
doaj   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study

Frontiers in Pharmacology, 2021
Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited.Methods: Ninety-
D. J Ouyang, D. J Ouyang, Q. T Chen, M. Anwar, N. Xie, Q. C. Ouyang, P. Z. Fan, L. Y. Qian, G. N. Chen, E. X. Zhou, L. Guo, X. W. Gu, B. N. Ding, X. H. Yang, L. P. Liu, C. Deng, Z. Xiao, J. Li, Y. Q. Wang, S. Zeng, Shouman Wang, Wenjun Yi   +21 more
doaj   +1 more source

The Discovery of Lapatinib (GW572016) [PDF]

Molecular Cancer Therapeutics, 2011
Commentary on: [David W. Rusnak, Karen Lackey, Karen Affleck, Edgar R. Wood, Krystal J. Alligood, Nelson Rhodes, Barry R. Keith, Doris M. Murray, W. Blaine Knight, Robert J. Mullin, and Tona M. Gilmer.
David, Rusnak, Tona M, Gilmer
openaire   +2 more sources

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

Neoplasia: An International Journal for Oncology Research, 2015
Heparanase (HPSE) is the dominant mammalian endoglycosidase and important tumorigenic, angiogenic, and pro-metastatic molecule. Highest levels of HPSE activity have been consistently detected in cells possessing highest propensities to colonize the brain,
Lixin Zhang, Jason A. Ngo, Michael D. Wetzel, Dario Marchetti   +3 more
doaj   +1 more source